CJJD Archives - Blue Horseshoe Stocks

Serious Options Runners, New Plays

Tuesday’s Clean Options Sweep:

It was another beautiful day for our options trading prospects on Tuesday. We lofted four potential plays in our premarket report and every single one returned significant intraday movement and thus a chance to bag some quick profits on the session.

Out specific targets of interest were the LMT Weekly $495-500 Calls, the BAC Weekly $30-31 Calls, the GS Weekly $330-325 Puts, and the JNJ Weekly $165-167.50 Calls. With the exception of only two contract sets in the entirety of those ranges, which posted percentage swings in the 90’s, every other strike yield double-bag moves or better! Here are the ranges and total possible gains they produced:

LMT Weekly $495-500 Calls
$495: 6.50-13.60 (+109%)
$497.50: 4.60-11.30 (+146%)
$500: 3.70-10.06 (+172%)
_____

BAC Weekly $30-31 Calls
$30: .30-.78 (+160%)
$30.50: .14-.43 (+207%)
$31: .07-.20 (+186%)
_____

GS Weekly $330-325 Puts
$330: .91-1.79 (+97%)
$327.50: .52-1.06 (+104%)
$325: .30-.58 (+93%)
_____

JNJ Weekly $165-167.50 Calls
$165: .07-.35 (+400%)
$167.50: .02-.11 (+450%)

Fresh Option Ideas:
NFLX Weekly $327.50-322.50 Puts
ISRG Weekly $287.50-292.50 Calls
MS Weekly $87.50-86 Puts
SPY 04/19 $413-412 Puts

Extended Watchlist:
GETR, VRAX, CJJD, WAL, SECO, HCNWF, ABML, GMZP, MEEC

Blue Horseshoe Stocks: Friday Wrap-Up

Wrapping Up a Solid Week

Once again, we’ll turn in our cards for the week with multiple multi-bag winners. Our quick-strike options ideas are second to none. We’d invite anyone who disputes that to point us to a better options newsletter!

We’ve been running with FDX and MU since Wednesday morning’s premarket report. We had already seen gains in the 500% range on FDX and the 100-200% range on MU that day.

We continued to monitor the FDX calls, as well as roll up to a higher strike price on MU for yesterday’s session. Once again we met with great success. So, first thing this morning, we want to take a look at the updated figures of the total possible gains on these plays.

FedEx Corp. FDX – Weekly $157.50-160 Calls.

$157.50 Calls – Range: .59-6.60 – Max Gain: 1017%
$160 Calls – Range: .35-4.40 – Max Gain: 1157%
_____

Micron Technology, Inc. MU – Weekly $37 Calls.

$37 Calls – Range: .31-1.39 – Max Gain: 348%

We’re going to roll up on MU once again to stay close to the action, and will be tracking the $38-38.50 Calls as we close out out another great week for options trading. Just remember, never trade options with a weekly expiration on Friday unless you’re an expert level trader with access to disposable funds!
_____

More Fresh Options Ideas
STZ Weekly $197.50-202.50 Calls
SPY Weekly $292 Calls

J.Jill, Inc. JILL

We also wanted to provide a quick update on a stock we tagged for observation a couple of weeks back on the 12th. JILL had been building a solid base and moving up slowly since then, up until yesterday when it really kicked things into another gear.

We observed a low of 1.54 subsequent to our initial alert, and yesterday’s new high came in at 2.29, marking an upswing of 49%

Extended Watchlist:
DMPI, FRSX, CUR, AREX, RAD, NAK, PSN, ACST, PHUN, OBLN, CJJD, NAKD, HAIR, JAGX, ATAI

Blue Horseshoe Stocks: Prime Bottom Play

CarMax, Inc. KMX – Recap

To open things up this week, we’re going to go over the performance of a fresh options ideas from Friday morning’s premarket report. We were tracking the KMX Weekly $85-87.50 Calls and we met with some very good fortune in the form of multi-bag, single session gain opportunities.

All four of the contract sets we watching provided enormous intraday chances, which wasn’t surprising, given the huge help we had last week from a surge in the markets. A strong earnings report from KMX did the rest, and we finished out the week with these superb gains:

$85 Calls – Range: .48-2.55 – Max Gain: 431%
$86 Calls – Range: .27-1.73 – Max Gain: 541%
$87 Calls – Range: .15-1.09 – Max Gain: 627%
$87.50 Calls – Range: .10-.76 – Max Gain: 660%

Fresh Ideas:

Seres Therapeutics, Inc. MCRB

We’re currently very interested in MCRB for multiple reasons. The stock recently touched down on a new annual low, and at the same time, a company director purchased a huge block of shares which amounted to a significant percentage of the overall market cap.

Since then the stock has been trending off of that bottom, with just the sort of volatility potential we’re always after. In addition to the stock itself being a solid candidate for a recovery play, we will also place the MCRB 07/19 $2.50 Calls on watch.

Extended Watchlist:
ACST, MEIP, VIVE, GSV, OBLN, BPMX, NBRV, CJJD

Blue Horseshoe Stocks: WATT Recap, NDRM & More

Energous Corp. WATT

We first began tracking WATT on Wednesday of last week, and on that day we witnessed a low of 8.40. Yesterday, just three sessions later, the stock bullrushed its way to a high of 11.20, a highly respectable three-day increase of 33%

This is one that will remain on our watchlist heading into this week’s holiday break, and in order for us to remain interested we’ll want to see the stock maintain support in the 9.60-10.75 range.

Amazon.com, Inc. AMZN – Options Idea

AMZN started flirting with the 50 DMA ($311) getting above it yesterday for the first time in a few weeks. Chart conditions are ripe with RSI just getting above the 50 line and the MACD having just underwent a bullish cross as we point out in the snapshot below.

As a result of these conditions, we want to radar the January 17th $300-315 Calls which closed yesterday at 15.62 and 6.53 respectively.

NeuroDerm Ltd. NDRM

NDRM, having just come off of a relative bottom, is flying high in the premarket this morning, gapping up to tune of 30% The company announced enccouraging top-line results for one of their treatments currently in testing, and the reaction is being felt on the chart.

We will be looking at this play the way we do most stock that are surging hard on news; observing for profit-takers to cause a pullback off of the top, and a dip-and-rip where we can take advantage of the subsequent rebound.

TODAY’S NEWS:

NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease (Tue 7:00AM EST)

Extended Watchlist:
BGMD, CJJD, XNPT, ARCP, ANV

Blue Horseshoe Stocks: CNET Recap & More

ChinaNet Online Holdings, Inc. CNET

CNET made an excellent move following its inclusion in yesterday’s morning report, as the stock would go on to trade in an impressive range from a low of 2.41 up to a new annual high of 3.98 on nearly 34x its one-month average volume. The strong 65% intraday run came in the first hour of trading, so folks had the chance at some very rapid, very substantial gains. Congrats if you were among them!

Direxion Daily Jr Gld Mnrs Bear 3X ETF (JDST)

We introduced JDST as a way to leverage against the falling prices of gold yesterday, and it’s working out in our favor so far. This ETF didn’t waste any time Monday morning, as it began a morning ascent that would last all day and carry it from a low of 14.65 to 16.88, a modest yet solid gain of 15%

We’ll have our eyes on this one for as long as it appears that the dollar will continue to strengthen.

OTHER ITEMS OF INTEREST

Our scanner yielded three interesting plays with news out of varying subjects.

NXT-ID, Inc. NXTD, has a mobile wallet product that they bill as the truly the first universal secure payment solution, which, as it does not require a smart-phone, provides certain advantages over other eWallet-type products now being pushed by Apple (ApplePay) among others. The stock made a significant move in yesterday’s trading, and will be on our radars today. >>> Shareholder Update PR

China Jo-Jo Drugstores, Inc. CJJDreleased financials yesterday and received a warm reception from traders. Some of the highlights included:

Online sales contributed $2.6 million in revenue, an increase of 103.5% from the comparable quarter of prior year
Retail sales, which includes online sales, accounted for approximately 80.0% of total revenue, and increased by $2.3 million, or 20.7% year over year to $13.2 million
Wholesale, which accounted for approximately 20.0% of total revenue, decreased to $3.3 million from $4.4 million for the same quarter of last year. >>> VIEW FULL PR

Synthetic Biologics, Inc. SYN Earlier last wee the FDA granted orphan drug status to SYN’s monoclonal antibody (mAb) combination, “SYN-005”. After a period of consolidation off of the initial run that produced, the stock is gapping up in the premarket today, so we’ll definitely want to keep an eye peeled.

Extended Watchlist:
OTIV, NETE, NVAX, USAT